华纳药厂撤回利多卡因凝胶贴膏注册申请

Core Viewpoint - Warner Pharmaceuticals has voluntarily withdrawn its drug registration application for Lidocaine Gel Patch, which is primarily used for alleviating postherpetic neuralgia, indicating a strategic decision based on research and development considerations [1] Group 1: Company Actions - The company received a termination notice from the National Medical Products Administration regarding the drug registration application for Lidocaine Gel Patch [1] - Warner Pharmaceuticals submitted the application for market approval in March 2025, which was accepted by the regulatory authority [1] - The decision to withdraw the application will not have a significant impact on the company's current or future operations and performance [1]